31 results about "CXCL9" patented technology

The invention discloses a preparation method and application of polypeptide hydrogel loaded with modified CAR-T cells and CXCL9, and creatively discovers that the combination of the modified CAR-T cells and the CXCL9 has a remarkable synergistic effect on treatment of melanoma for the first time. According to the invention, efficient enrichment of CAR-T cells at a focus part is realized through the hydrogel delivery system, the local curative effect is improved, in addition, the introduction of CXCL9 further enhances the tumor infiltration capability and the treatment effect of the CAR-T cells, a brand new treatment scheme is provided for tumor treatment, and the clinical application prospect is wide.

The present application relates to a kind of molecular marker group of human esophageal squamous cell carcinoma and its application, the molecular marker group is: the molecular marker group that the esophageal squamous cell carcinoma is divided into differentiation type, immune type, metabolic type, cell stem type: differentiation type: LCE3D, CDSN, KLK5, SPRR2G and DSG1;Immune type: MS4A1, CD79A, CXCL9, MZB1 and IDO1;Metabolic type: GSTA1, ADH7, UGT1A3 and ALDH3A1;Cell stem type: WFDC2, PEG10, SFRP1, LGR6 and VWA2;And the NK cell surface molecular marker group that the esophageal squamous cell carcinoma is divided into prognosis bad and drug insensitivity subtype.

The invention relates to application of a monocarboxylic acid transporter 1 inhibitor in preparation of a medicine for preventing, relieving and / or treating pancreatic cancer. By using the MCT1 inhibitor, the lactic acid level in the pancreatic stellate cells PSCs is effectively reduced, so that the lactic acid of Vps34 is inhibited, and the activation process of autophagy-dependent PSCs mediated by the lactic acid is blocked. By inhibiting the activation of the PSCs, the MCT1 inhibitor further reduces the secretion of downstream chemokines CXCL9 and CXCL10. The CXCL9 and the CXCL10 are key factors for inducing CD8 + T cells to up-regulate PD-1 expression through CXCR3 and STAT3 signal channels, so that the MCT1 inhibitor substantially cuts off an induction signal causing CD8 + T cell depletion on the upstream, further, the in-vivo growth and in-situ tumorigenesis ability of pancreatic cancer can be inhibited, and the purpose of preventing, relieving and / or treating pancreatic cancer is achieved.

This disclosure provides a method for treating a cancer patient comprising administering to the patient a therapeutically effective amount of an anti-PD-1 antagonist, for example, an anti-PD-1 or anti-PD-L1 antibody, in combination with an indolamine 2,3-dioxygenase inhibitor, wherein the patient is identified as exhibiting a combined biomarker comprising (a) a high IFNγ inflammatory signature score and (b) a low tryptophan 2,3-dioxygenase 2 (TDO2) gene expression score. The high IFNγ inflammatory signature score is determined by measuring the expression of a panel of IFNγ-related inflammatory genes in a cancer sample obtained from the patient, wherein the gene panel comprises, for example, IFNγ, CXCL10, CXCL9, HLA-DRA, IDO1, and STAT1. In some respects, the gene panel also includes CCR5, CXCL11, GZMA, and PRF1.In some aspects, the genetic panel comprises CXCR6, TIGIT, PD-L1, PD-L2, LAG3, NKG7, PSMB10, CMKLR1, CD8A, IDO1, CCL5, CXCL9, HLA.DQA1, CD276, HLA.DRB1, STAT1, HLA.E and TDO2.

The disclosure provides a method for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-PD-1 antagonist, e.g., an anti-PD-1 or anti-PD-L1 antibody, in combination with an indoleamine 2,3-dioxygenase inhibitor, wherein the subject is identified as exhibiting a combined biomarker comprising (a) a high IFNγ inflammatory signature score and (b) a low tryptophan 2,3-dioxygenase 2 (TDO2) gene expression score. The high IFNγ inflammatory signature score is determined by measuring the expression of a panel of IFNγ related inflammatory genes in a cancer sample obtained from the subject, wherein the gene panel comprises, e.g., IFNγ, CXCL10, CXCL9, HLA-DRA, IDO1, and STAT1. In some aspects, the gene panel further comprises CCR5, CXCL11, GZMA, and PRF1. In some aspects, the gene panel comprises CXCR6, TIGIT, PD-L1, PD-L2, LAG3, NKG7, PSMB10, CMKLR1, CD8A, IDO1, CCL5, CXCL9, HLA.DQA1, CD276, HLA.DRB1, STAT1, HLA.E, and TDO2.

Methods for treating or inhibiting fibrosis in a subject by administering specific chemokine cocktails are described. The chemokine cocktails include combinations of CXCL4, CXCL9, CXCL10, CXCL11 and / or CXCL12 proteins, or the combination of CXCL1 and CXCL8 proteins. Methods for increasing extracellular matrix (ECM) production and / or treating a wound in a subject by administering specific chemokine cocktails are also described. In these methods, the cocktails include CXCL1 and CXCL8 proteins and optionally further include a CCL2 protein.

Disclosed are biomarker-based methods of treatment, monitoring, and diagnosis for IL-17 dependent conditions, including hidradenitis suppurativa. The biomarker may be selected from the group consisting of IL6, PLA2G2A, IL19, PI3, CST7, IL17A, IL17F, GH1, MZB1, IL1B, IFNG, TNC, CXCL9, SLAMF7, VEGFA, IL17C, SLAMF1, SDC1, OSM, LBP, REG3A, CD79B, COL4A1, CLEC4D, VWF, IL5RA, CSF3, TGFA, IL2RA, ITIH3, FCAR, CCL23, NRCAM, RETN, SERPINA11, CLEC4G, CSF1, HGF, CRELD2, EFEMP1, LTBR, NME3, kits for measuring biomarkers, diagnosing and treating IL-17 dependent conditions, and identifying superresponders are also disclosed.

The invention relates to the field of bioengineering, in particular to a function-synergetic bionic gene editing carrier system as well as a preparation method and application thereof. The invention provides a gene editing expression box. The gene editing expression box comprises a cancer cell specific promoter, a CXCL9 gene, an sgBAG3 gene and an sgHSP70 gene. A bionic lipid carrier with protein adsorption resistance, cancer cell targeting and membrane fusion delivery is constructed, and an integrated gene editing CRISPR system capable of highly expressing CXCL9 protein factors in cancer cells and double editing tumor cell BAG3 and HSP70 genes is entrapped, so that a multifunctional synergetic bionic gene editing carrier system is constructed; according to the invention, in-vivo delivery stability of the CRISPR system, cancer cell targeting accuracy and intracellular release high efficiency are realized, liver cancer cell gene editing efficiency is improved, a T cell killing enhancement effect tumor immune microenvironment is constructed, and effective cancer resistance of the CRISPR system in a tumor environment is realized.

The invention provides a COPD (chronic obstructive pulmonary disease) target protein based on plasma proteomics. The target protein comprises one or more of the following four proteins: HLA-DRA (human leukocyte antigen-DRA), CXCL9, TNFRSF8 and RNASET2. The invention not only highlights the important value of longitudinal proteomics analysis in revealing the early biological change of COPD, but also opens up a new path for the development of personalized treatment schemes. In view of the complex function of protein in the biological regulation and control process, the research result of the invention provides an important framework for understanding the pathological mechanism of COPD, and lays a foundation for developing a treatment strategy based on proteomics in the future. The invention also provides an application based on the COPD target protein and a medicine for treating COPD.

To provide cleavable activators of CXCR3 and methods of use.SOLUTION: Disclosed is a recombinant C-X-C motif chemokine ligand (CXCL) peptide modified to introduce a cleavage site for a protease (e.g., a protease that is activated during an inflammation response). The CXCL peptide has an ability to activate CXCR3 until the protease cleaves the peptide. The proteolytic cleavage of the CXCL peptide minimizes pro-inflammatory response and inhibits the development of fibrosis. The CXCL may be CXCL10, CXCL4, CXCL9 or CXCL11.SELECTED DRAWING: None

The present invention provides agents and compositions for increasing expression of a CXCL9 and / or CXCL10 gene by targeting expression control region associated with CXCL9 and / or CXCL10 gene and methods of use thereof for treating a disease or disorder associated with CXCL9 and / or CXCL10, e.g., cancer.

The invention discloses application of PTGDS, APOF and CXCL9 as biomarkers, and application of the biomarkers in preparation of products for early diagnosis of diabetic nephropathy and diabetes mellitus. According to the marker, related differential proteins are analyzed through combination of DIA (non-targeted data independent acquisition) and targeted Olink proteomics sequencing, then analysis and verification are performed through machine learning and enzyme-linked immunosorbent assay, and the key effect of the expression levels of PTGDS, APOF and CXCL9 in diabetes and diabetic nephropathy is proved. The invention finds that the combined characteristics of PTGDS, APOF and CXCL9 can be used as the marker for early diagnosis of DKD and DM for the first time, has sensitivity, specificity and accuracy, and has important clinical value.

The present invention pertains to a new method for the diagnosis, prognosis, stratification and / or monitoring of a therapy, of a pulmonary dysfunction in a subject. The method is based on the determination of the level of a panel of biomarkers selected from TM4SF18, TRGV9, ADORA2A, H963, IRF2, TNFSF14, TRIB1, SMAD3, TSLP, SLAMF8, THBS1, SOD1, HAS2, TLR2, THBD, TRA, TFEC, SPHK1, COL3A1, Elastin, IL6R, SN, TEK, SOX7, CXCL9, CXCL10, SLC38A6, SLC15A3, TGFA, SLPI, VWF, TLR8, TGFB1, CXCR6, CCL24, PD1, PLA1A, TRD, CTLA4, MMP9, CD301, PDL1, PDL2, TGFB1, CXCR6, CCL24, PD1, PLA1A, TRD, CTLA4, MMP9, and CD301. The new biomarker panels of this invention allow diagnosing and even stratifying various pulmonary dysfunctions in a subject, and even allow early detection of Chronic lung allograft dysfunction (CLAD). Furthermore provided are diagnostic kits for performing the methods of the invention.

The invention relates to the field of biological medicine, and discloses application of an SMURF1 inhibitor, a synergistic immune composition and application of the synergistic immune composition. The SMURF1 inhibitor can be used for preparing drugs for regulating and controlling CD8 + T cell infiltration in a tumor immune microenvironment, and can up-regulate the STAT1 protein level and promote the expression of CXCL9 and CXCL10, thereby enhancing immune response and inhibiting tumor growth. The SMURF1 inhibitor is combined with the PD-1 and / or PD-L1 inhibitor for use, the anti-tumor curative effect can be further improved, and the SMURF1 inhibitor is suitable for tumor treatment related to SMURF1 expression up-regulation or activity abnormity.

This invention discloses a set of biomarkers, scoring models, and applications for assessing immunotherapy response and / or prognosis in head and neck squamous cell carcinoma, relating to the field of biomedical technology. The biomarkers include ITGB1, FTH1, SPP1, CD3D, CXCL9, and IL2RB. The STRIDE score is obtained by calculating the geometric mean ratio of the expression levels of the aforementioned six biomarkers, which can be used to assess the likelihood of high or low response to immunotherapy and / or prognostic risk in subjects. This invention constructs a spatial domain scoring model based on the D4 and D5 / D6 spatial domains to obtain the STRIDE score, reflecting the patient's spatial immune status, thereby enabling the assessment of prognostic risk and the suitability of immunotherapy for patients with head and neck squamous cell carcinoma.

The invention provides an immune-related adverse reaction marker and a kit. The immune-related adverse reaction marker and the kit can effectively predict immune-related adverse reaction caused by programmed death receptor 1 antibody / programmed death ligand antibody treatment. The immune-related adverse reaction marker comprises CCL20, CXCL11, CXCL10 or CXCL9, and the immune-related adverse reaction marker comprises CCL20, CXCL11, CXCL10 or CXCL9. The immune-related adverse reaction marker and the kit provided by the technical scheme of the invention can effectively predict immune-related adverse reactions, so that the immune-related adverse reactions can be conveniently intervened and treated.

The invention relates to the technical field of synthetic biology and lung cancer treatment, in particular to an aptamer-coupled engineering bacterium and application thereof in treatment of non-small cell lung cancer. Specifically, escherichia coli is taken as an original strain for the first time, a gene for coding the immune chemotactic factor CXCL9 is introduced into the original strain to obtain an engineering bacterium capable of expressing and secreting the immune chemotactic factor, the engineering bacterium is coupled with an aptamer, and the aptamer can specifically recognize and combine tumor-associated antigens or cell surface receptors. In addition, the invention also proves that the aptamer-coupled escherichia coli for expressing the immune chemotactic factor CXCL9 can specifically target solid tumors (especially non-small cell lung cancer) and inhibit the growth of the solid tumors in an organism for the first time through experiments in the organism.

The present invention provides agents and compositions for increasing expression of a CXCL9 and / or CXCL10 gene by targeting expression control region associated with CXCL9 and / or CXCL10 gene and methods of use thereof for treating a disease or disorder associated with CXCL9 and / or CXCL10, e.g., cancer.

This invention relates to a novel strain of Prevotella merde immunoactis and its uses. The inventors have confirmed that the novel strain of Prevotella merde immunoactis (deposit number: KCTC 14922BP) not only increases T cell proliferation, increases T cell IFN-γ secretion, increases the expression or activity level of IFN-γ or Cxcl9, and decreases the expression or activity level of Ccl22, but also enhances the anticancer effect of immune checkpoint inhibitors. Therefore, the novel strain of Prevotella merde immunoactis or its culture medium is expected to be useful for immune enhancement and enhancing the anticancer effect of immune checkpoint inhibitors.

The present application provides an immune-related adverse event marker and a kit, which can effectively predict immune-related adverse events caused by the treatment of a programmed death receptor 1 antibody / programmed death ligand antibody. The immune-related adverse event marker includes: CCL20, CXCL11, CXCL10 or CXCL9. The immune-related adverse event marker and kit provided by the technical solution of embodiments of the present application can effectively predict immune-related adverse events, thereby facilitating therapeutic intervention for immune-related adverse events.

This method for predicting the effectiveness of dupilumab administration to an atopic dermatitis patient comprises a step for measuring the concentration of at least one biomarker in a blood sample derived from the patient before dupilumab administration, wherein: the concentration of the biomarker is an indicator for predicting the effectiveness of the dupilumab administration; and the biomarker is selected from the group consisting of interleukin (IL)-22, C-C Motif Chemokine Ligand (CCL) 20, IL-18, IL-17, Tumor Necrosis Factor (TNF)-α, and C-X-C Motif Chemokine 9 (CXCL9).

Biomarker-based treatment, monitoring, and diagnostic methods for IL-17 dependent conditions, including hidradenitis suppurativa, are disclosed. The biomarkers may be selected from IL6, PLA2G2A, IL19, PI3, CST7, IL17A, IL17F, GH1, MZB1, IL1B, IFNG, TNC, CXCL9, SLAMF7, VEGFA, IL17C, SLAMF1, SDC1, OSM, LBP, REG3A, CD79B, COL4A1, CLEC4D, VWF, IL5RA, CSF3, TGFA, IL2RA, ITIH3, FCAR, CCL23, NRCAM, RETN, SERPINA11, CLEC4G, CSF1, HGF, CRELD2, EFEMP1, LTBR, NME3, CKAP4, CD276, SPON2, GGH, TIMP1, LY9, MCFD2, TCN2, QPCT, HYOU1, TNSFSF13B, CCL2, CCL3, CCL4, CCL5, CCL7, CCL20, CXCL1, CXCL8, PDFGA, CXCR2, CCR6, CXCL13, PCDH1, BOC, MEPE, ADAM23, THOP1, IL1RL2, RCOR1, EDAR, and combinations thereof. Kits for measuring the biomarkers, diagnosing and treating IL-17-dependent conditions, and identifying super-responders are also disclosed.

The present invention relates to the diagnosis and treatment of conditions in patients with elevated levels of CXCL9 and other biomarkers. Methods and compositions for the treatment of hemophagocytic lymphocytosis (HLH) are provided. The present disclosure also generally relates to methods and compositions for diagnosing and treating conditions associated with elevated levels of CXCL9, elevated levels of total IFN gamma, and other biomarkers. The present disclosure also relates to methods of treating, delaying the progression or otherwise ameliorating the symptom of a condition in a patient with elevated levels of CXCL9, elevated levels of total IFN gamma and other biomarkers using agents that intervene in or otherwise antagonize interferon gamma (IFN gamma) signaling, including neutralizing anti-IFN gamma antibodies.

The invention relates to the field of biomedicine, and discloses a prediction model for myocarditis related to a hormone-resistant immune checkpoint inhibitor. The invention discloses application of a marker combination CXCL9, MMP1 and TRANCE in construction of a myocarditis prediction model related to a hormone-resistant immune checkpoint inhibitor, and constructs the myocarditis prediction model related to the hormone-resistant immune checkpoint inhibitor, the model has high prediction efficiency (AUC = 0.91), and a reliable prediction model is provided for early recognition of srICIAM patients.

To provide a method for treating cancer or solid tumors in combination with an immune checkpoint inhibitor therapy.SOLUTION: A method for treating cancer or a solid tumor in a subject, the method comprising: a. administering to the subject (i) a CXCL9 polypeptide, a CXCL10 polypeptide, or a combination thereof, (ii) a polynucleotide encoding the CXCL9 polypeptide, a polynucleotide encoding the CXCL10 polypeptide, or a combination thereof, (iii) cells comprising the polynucleotide encoding the CXCL9 polypeptide, cells comprising the polynucleotide encoding the CXCL10 polypeptide, or a combination thereof, or (iv) any combination thereof; and b. administering an immune checkpoint inhibitor to the subject.SELECTED DRAWING: Figure 5C

The invention discloses a self-adjuvant gel and an application of the self-adjuvant gel in tumor immunotherapy. According to the gel, N-acetylcysteine (NAC) is grafted with chitosan to form a sulfydryl-containing functional carrier, and the activity of T cells is effectively maintained by utilizing the interaction between NAC and sulfydryl on the surfaces of the T cells; meanwhile, the oxidized beta-glucan has Toll-like receptor 4 activation capability, and can promote the maturation and activation of dendritic cells. The formation of the gel depends on a Schiff base reaction between an aldehyde group in the oxidized beta-glucan and an amino group of the chitosan, and self-assembly gel formation under a mild condition is realized. The system can load a chemotactic factor CXCL9 and a tumor antigen at the same time, efficient recruitment of T cells is achieved by continuously releasing the CXCL9, and the antigen is synchronously and slowly released to induce specific immune response. The self-adjuvant gel has the functions of immune cell recruitment, antigen delivery and immune activation, and provides a novel material platform and strategy for tumor immunotherapy.

This invention discloses a dynamic monitoring and analysis system for immune inflammation in patients with glomerular diseases, applicable to the field of medical testing and data analysis. The system includes a data acquisition module, a multi-omics detection module, a dynamic data analysis module, a visualization and reporting module, and an early warning module. The multi-omics detection module integrates the joint detection of immune inflammation-related proteins (such as CCL11 and CXCL9), metabolic markers (such as N-acetyl-L-leucine), and oxidative stress markers (such as RAC2). The dynamic data analysis module is built based on the XGBoost algorithm and calculates a "dynamic immune score" to quantitatively assess disease activity and predict trends. This invention overcomes the shortcomings of traditional single-marker methods, such as poor specificity and inability to dynamically monitor, achieving non-invasive, multi-dimensional, and real-time monitoring of the immune inflammatory status of glomerular diseases, providing decision support for precise clinical diagnosis and treatment.

The present invention provides agents and compositions for reducing expression of a CXCL9, CXCL10, and / or CXCL11 gene by targeting expression control region associated with CXCL9, CXCL10, and / or CXCL11 gene and methods of use thereof for treating a disease or disorder associated with CXCL9, CXCL10, and / or CXCL11, e.g., liver disease.

The invention discloses an interferon IFN alpha with immunological enhancement activity on juvenile grouper and a preparation method and application thereof, the nucleotide sequence of the interferon IFN alpha is as shown in SEQ ID NO: 1, the amino acid sequence of the interferon IFN alpha is as shown in SEQ ID NO: 2, and the interferon IFN alpha is transferred into the body of the juvenile grouper to play a role through intracellular expression of yeast and protection of the yeast. Through preliminary verification, the interferon IFN alpha can promote up-regulation of expression of juvenile grouper immune genes IFIT1, IRF6, TNF-b, TLR21 and CXCL9, and can be developed into a natural fish immunopotentiator or immunologic adjuvant.

Described are expression cassettes encoding CD3-half-BiTE, CXCL9 and CTLA-4 scFv. The described expression cassettes can be used to treat cancer in a subject. Methods of delivering the expression cassettes to a tumor by direct intratumoral injection and electroporation are also described.